Literature DB >> 21402129

Positron emission tomography with 11C-flumazenil in the rat shows preservation of binding sites during the acute phase after 2 h-transient focal ischemia.

S Rojas1, A Martín, D Pareto, J R Herance, S Abad, A Ruíz, N Flotats, J D Gispert, J Llop, V Gómez-Vallejo, A M Planas.   

Abstract

BACKGROUND AND
PURPOSE: Positron emission tomography (PET) studies in humans have used (11)C-flumazenil (FMZ) to assess neuronal viability after stroke. Here we aimed to study whether (11)C-FMZ binding was sensitive to neuronal damage in the acute phase following ischemia/reperfusion in the rat brain. EXPERIMENTAL PROCEDURES: Transient (2 h followed by reperfusion) and permanent intraluminal middle cerebral artery occlusion was carried out. (11)C-FMZ binding was studied by PET up to 24 h after the onset of ischemia. Tissue infarction was evaluated post-mortem at 24 h. Immunohistochemistry against a neuronal nuclei specific protein (NeuN) was performed to assess neuronal injury.
RESULTS: No decrease in (11)C-FMZ binding was detected in the ipsilateral cortex up to 24 h post-ischemia in the model of transient occlusion despite the fact that rats developed cortical and striatal infarction, and neuronal injury was clearly apparent at this time. In contrast, (11)C-FMZ binding was significantly depressed in the ipsilateral cortex at 24 h following permanent ischemia.
CONCLUSIONS: This finding evidences that (11)C-FMZ binding is not sensitive to neuronal damage on the acute phase of ischemia/reperfusion in the rat brain.
Copyright © 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21402129     DOI: 10.1016/j.neuroscience.2011.03.013

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  8 in total

1.  Mapping the dynamics of brain perfusion using functional ultrasound in a rat model of transient middle cerebral artery occlusion.

Authors:  Clément Brunner; Clothilde Isabel; Abraham Martin; Clara Dussaux; Anne Savoye; Julius Emmrich; Gabriel Montaldo; Jean-Louis Mas; Jean-Claude Baron; Alan Urban
Journal:  J Cereb Blood Flow Metab       Date:  2015-12-31       Impact factor: 6.200

Review 2.  PET imaging in multiple sclerosis.

Authors:  Daniele de Paula Faria; Sjef Copray; Carlos Buchpiguel; Rudi Dierckx; Erik de Vries
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-09       Impact factor: 4.147

3.  Early-stage 11C-Flumazenil PET predicts day-14 selective neuronal loss in a rodent model of transient focal cerebral ischemia.

Authors:  Jessica L Hughes; John S Beech; P Simon Jones; Dechao Wang; David K Menon; Franklin I Aigbirhio; Tim D Fryer; Jean-Claude Baron
Journal:  J Cereb Blood Flow Metab       Date:  2019-10-22       Impact factor: 6.200

4.  Imaging of perfusion, angiogenesis, and tissue elasticity after stroke.

Authors:  Abraham Martín; Emilie Macé; Raphael Boisgard; Gabriel Montaldo; Benoit Thézé; Mickael Tanter; Bertrand Tavitian
Journal:  J Cereb Blood Flow Metab       Date:  2012-04-11       Impact factor: 6.200

5.  Imaging Neuroinflammation - from Bench to Bedside.

Authors:  Benjamin Pulli; John W Chen
Journal:  J Clin Cell Immunol       Date:  2014

6.  Parametric Imaging of [11C]Flumazenil Binding in the Rat Brain.

Authors:  Isadora Lopes Alves; David Vállez García; Andrea Parente; Janine Doorduin; Ana Maria Marques da Silva; Michel Koole; Rudi Dierckx; Antoon Willemsen; Ronald Boellaard
Journal:  Mol Imaging Biol       Date:  2018-02       Impact factor: 3.488

7.  Pharmacokinetic modeling of [11C]flumazenil kinetics in the rat brain.

Authors:  Isadora Lopes Alves; David Vállez García; Andrea Parente; Janine Doorduin; Rudi Dierckx; Ana Maria Marques da Silva; Michel Koole; Antoon Willemsen; Ronald Boellaard
Journal:  EJNMMI Res       Date:  2017-02-22       Impact factor: 3.138

Review 8.  Selective neuronal loss in ischemic stroke and cerebrovascular disease.

Authors:  Jean-Claude Baron; Hiroshi Yamauchi; Masayuki Fujioka; Matthias Endres
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-06       Impact factor: 6.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.